TABLE IV -.
Probability of transition associated with state of health in the acute phase
| Treatment | NoNC | aStroke | aMI | Death |
|---|---|---|---|---|
| PEX and immunosuppression | 79.10% | 3.90% | 3.80% | 13.20% |
| Caplacizumab + PEX and immunosuppression | 93.40% | 2.70% | 3.90% | 0.00% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.